ProCE Banner Activity

CE / CME

Alpha-1 Antitrypsin Deficiency: Improving Early Detection and Management of Liver Disease

Clinical Thought

Liver disease caused by AATD is easy to miss until it is too late. Simple screening measures can detect it and help with disease prevention.

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Released: April 29, 2025

Expiration: April 28, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This educational activity is intended for physicians (including residents and fellows), nurse practitioners, and physician associates practicing in gastroenterology, hepatology, pulmonology, and primary care.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Genetic Diseases.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Identify patients who should be screened for AATD.

  • Implement recommended diagnostic procedures for patients with suspected AATD.

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Rohit Loomba, MD, MHSc: consultant/advisor/speaker: 89Bio, Aardvark, Altimmune, Arrowhead, AstraZeneca, Cascade, Gilead, Glympse Bio, Inipharma, Intercept, Inventiva, Ionis, Janssen, Lilly, Lipidio, Madrigal, Merck, Neurobo, Novo Nordisk, Pfizer, Sagimet, Takeda, Terns, Viking; stock options: Sagimet Biosciences; research grants paid to institution: Arrowhead, Astrazeneca, Boehringer Ingelheim, Bristol Myers Squibb, Galectin, Gilead, Hanmi, Intercept, Inventiva, Ionis, Janssen, Lilly, Madrigal, Merck, Novo Nordisk, Pfizer, Sonic Incytes, Terns; co-founder: LipoNexus.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Katie Smiley, PA-C, as noted below:

Katie Smiley, PA-Cconsultant/advisor/speaker: Adma Biologics, Novartis.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 29, 2025, through April 28, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hour.

Physician Associate Continuing Medical Education

AAPA CME Accreditation - AAPA

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credit. Approval is valid until April 28, 2026. PAs should only claim credit commensurate with the extent of their participation.

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.